- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Two-Midnight Rule Will Short-Change Hospitals, Providers Say
Healthcare providers say Medicare is going to short-change them on patients who spend fewer than two nights in the hospital, and delaying implementation of a new payment policy until October won't change that.
Healthcare providers say Medicare is going to short-change them on patients who spend fewer than two nights in the hospital, and delaying implementation of a new payment policy until October won't change that.
What the delay will do is give hospitals, doctors and special-interest groups more time to study the new “two midnight” rule and find ways to block it—whether through negotiation, legislation or litigation.
“I think ultimately the hospitals will prevail on this, one way or another,” said Emily Evans, a partner with Nashville-based healthcare consultancy Obsidian Research Group. Hospitals say “short-stay inpatient care is common in the practice of medicine, and you shouldn't treat it like fraud, waste or abuse.”
Read the full story here: http://bit.ly/1doIyZh
Source: Modern Healthcare
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
